Respiratory Disease Vaccine Market (Disease Type - Chronic Obstructive Pulmonary Disease (COPD), Pertussis, Pneumonia, Measles, and Diphtheria; Vaccine - DTaP, PPSV23, MMR, Haemophilus Influenzae Type B (HIB), and Respiratory Syncytial Virus (RSV)): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

A recent report published by Infinium Global Research on respiratory disease vaccine market provides in-depth analysis of segments and sub-segments in the global as well as regional respiratory disease vaccine market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional respiratory disease vaccine market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global respiratory disease vaccine market.

Market Insight:

The global respiratory disease vaccine market was valued at over USD 18 billion in 2022 and is expected to reach more than USD 28 billion in 2030, with a CAGR of above 5% during the forecast period 2023-2030.

Respiratory diseases affect the lungs and other parts of the respiratory system. It is caused due to many reasons such as passive smoking, smoking tobacco, infection, asbestos, and a variety of diseases caused by air pollution. Chronic respiratory diseases are diseases of the airways and other structures of the lungs. The main problem is the treatment of these diseases only reduces the symptoms. Preventing respiratory diseases through vaccination help to decrease the subsequent burden of infection, reduce the need for hospitalizations, and also reduce antibiotic prescriptions for respiratory disease complications in children and adolescents. The most common vaccines such as pneumococcal vaccines, PCV13, and PPSV23, these two vaccines are recommended for all adults 65 years or older, particularly those with chronic lung conditions like COPD.

The prevalence of respiratory diseases such as asthma, tuberculosis, pneumonia, and lung cancer is driving the growth of the market. The two most common chronic respiratory diseases are asthma and Chronic Obstructive Pulmonary Disease (COPD). These both diseases affect the airways in the lungs. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases. Additionally, growing healthcare expenditure is also supporting the growth of the market. Although, strict policies by the government for the approval of vaccines may hamper the growth of the market. Moreover, the growing funding for respiratory disease vaccine research will provide a growth opportunity to expand the respiratory disease vaccine market.

North America is dominating region in the respiratory disease vaccine market owing to the rising prevalence of respiratory diseases. Chronic Respiratory Diseases (CRDs) are the leading causes of death and disability in the North America region. Which includes Chronic Obstructive Pulmonary disease (COPD), asthma, occupational lung diseases, pulmonary hypertension, and others. The rising number of patients in the region suffering from different respiratory diseases is supporting the growth of the market. Along with this, the governments in North America are taking initiatives and supporting the industry for R&D activities in the field of vaccination, high healthcare expenditure, and well-developed healthcare infrastructure. Asia-Pacific is expected to grow in the respiratory disease vaccine market during the forecast period due to the rising research and development activities, and increasing investment in the healthcare sector.

Report Scope of the Respiratory Disease Vaccine Market:

Segment Covered

The report on global respiratory disease vaccine market covers segments such as disease type, and vaccine. On the basis of disease type, the sub-markets include chronic obstructive pulmonary disease (COPD), pertussis, pneumonia, measles, and diphtheria. On the basis of vaccine, the sub-markets include DTaP, PPSV23, MMR, haemophilus influenzae type B (HIB), and respiratory syncytial virus (RSV).

Companies Profiled:

The report provides profiles of the companies in the market such as Sanofi, GSK plc, Merck & Co., Inc., Pfizer Inc., Bavarian Nordic, EMERGENT, CSL Limited, Moderna, Inc., Serum Institute of India Pvt. Ltd., and Sinovac Biotech.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the respiratory disease vaccine market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.